Ruzanna Papyan: The life-saving potential of anti-GD2 therapy in treating high-risk neuroblastoma

Ruzanna Papyan shared the following on LinkedIn:

”Week 2 of the Global Access To AntiGD2 Campaign.

This week, we highlight compelling evidence from the ANBL0032 clinical trial, emphasizing the life-saving potential of anti-GD2 therapy in treating high-risk neuroblastoma.

Published by the Children’s Oncology Group in 2010, the trial evaluated the addition of immunotherapy (dinutuximab) combined with isotretinoin, GM-CSF, and IL-2 to standard therapy. Results were remarkable, showing a statistically significant improvement in both event-free survival (66% vs. 46%) and overall survival (86% vs. 75%) at two years compared to isotretinoin alone.

These findings are crucial as they underline the dire need for global access to anti-GD2 therapies. Many regions worldwide still lack these essential treatments, leaving children with high-risk neuroblastoma vulnerable.

By advocating for the inclusion of anti-GD2 therapies in the World Health Organization Essential Medicines List, we can pave the way for broader access and hope for children fighting neuroblastoma worldwide.

Join us in our mission to make a difference. Your support, sharing of knowledge, and advocacy can change lives. Together, we can ensure that every child has access to the best fighting chance against neuroblastoma.

Stay tuned for more updates and stories as we push forward with the Global Access To AntiGD2 campaign. Let’s give every child the future they deserve.

Stay tuned for more updates and ways to get involved! Together, we can make a difference.”

Source: Ruzanna Papyan/LinkedIn

Ruzanna Papyan is a pediatric oncologist and clinical research physician at the Pediatric Cancer and Blood Disorders Center of Armenia, Hematology  Center after Prof. Yeolyan. She is also Head of the Musculoskeletal Multidisciplinary Working Group and Assistant Professor at the Department of Pediatric Oncology and Hematology at Yerevan State Medical University. Dr. Papyan coordinates educational sessions for the Global Neuroblastoma Network and holds the esteemed position of co-chair of the Adolescents and Young Adults Steering Group at the International Society of Paediatric Oncology (SIOP). She is a member of oncology societies, such as AAHO, SOHO, ESMO, ESO, and POEM. Her research interests include soft tissue and bone sarcomas, and neuroblastomas among children and young adults.